Brief: Seres Therapeutics Announces Two Transactions To Strengthen Balance Sheet, Reduce On-Going Lease Costs And Extend Projected Operating Cash Runway Well Into The First Quarter Of 2027
05/06/2026 12:10
BRIEF-Seres Therapeutics Announces Two Transactions To Strengthen Balance Sheet, Reduce On-Going Lease Costs And Extend Projected Operating Cash Runway Well Into The First Quarter Of 2027 June 5 (Reuters) - Seres Therapeutics Inc MCRB.O:
SERES THERAPEUTICS ANNOUNCES TWO TRANSACTIONS TO STRENGTHEN BALANCE SHEET, REDUCE ON-GOING LEASE COSTS AND EXTEND PROJECTED OPERATING CASH RUNWAY WELL INTO THE FIRST QUARTER OF 2027
SERES THERAPEUTICS - NESTLÉ HEALTH SCIENCE TO PAY SERES $25 MILLION IN 2026 FOR VOWST MILESTONE BUY-OUT
SERES THERAPEUTICS - RESTRUCTURES LEASE TO REDUCE ANNUAL FACILITY CASH COSTS AND LONG-TERM LEASE LIABILITY
Source text: ID:nGNX7gPcgs
Further company coverage: MCRB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Seres Therapeutics
See all newsChinese automakers make tech-led pitch for Europe's premium car market
Brief: Seres Therapeutics - May Offer Up To $300 Million Of Securities
Seres Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Seres Therapeutics Q2 net income turns positive on VOWST sale gain
Brief: Seres Therapeutics Q2 EPS USD 0.47